Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment

A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy

NCT05303558 ·Status: COMPLETED

Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

NCT00751790 ·Status: COMPLETED ·Phase: PHASE3

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350 ·Status: RECRUITING ·Phase: PHASE4

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

NCT01303692 ·Status: COMPLETED

A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy

NCT05759273 ·Status: COMPLETED

Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)

NCT03703778 ·Status: ACTIVE_NOT_RECRUITING

Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer

NCT00456144 ·Status: COMPLETED

CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer

NCT06306612 ·Status: RECRUITING ·Phase: NA

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

NCT05458856 ·Status: COMPLETED ·Phase: PHASE3

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

NCT06350825 ·Status: RECRUITING ·Phase: PHASE3

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

NCT01374087 ·Status: TERMINATED ·Phase: PHASE2

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

NCT00415246 ·Status: TERMINATED ·Phase: PHASE3

AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

NCT00519233 ·Status: COMPLETED ·Phase: PHASE1

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

NCT03017313 ·Status: COMPLETED

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

NCT00108290 ·Status: COMPLETED ·Phase: PHASE2

Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer

NCT01819285 ·Status: COMPLETED ·Phase: PHASE3

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

NCT01656161 ·Status: COMPLETED ·Phase: PHASE3

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

NCT05169112 ·Status: RECRUITING ·Phase: PHASE3

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

NCT03085966 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

NCT07163910 ·Status: RECRUITING ·Phase: PHASE2

Study to Find Maintenance Dose for Periodic Administration of ASP3550

NCT01261572 ·Status: COMPLETED ·Phase: PHASE2

Effect of ADT in Chinese Male With Prostate Cancer

NCT04341324 ·Status: COMPLETED

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

NCT04995042 ·Status: COMPLETED ·Phase: PHASE1

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

NCT01313273 ·Status: TERMINATED ·Phase: PHASE3

Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients

NCT05202340 ·Status: COMPLETED